Suraksha Diagnostic Limited (SURAKSHA) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Suraksha Diagnostic Limited ₹136, price ₹350, upside -61.2%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Suraksha Diagnostic Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
22‑month range ₹227.60 – ₹418.00 · fair‑value band ₹74.61 – ₹169.96 · the ₹350.15 price screens above the ₹135.97 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow Suraksha Diagnostic in your weekly email
Every Wednesday you see whether Suraksha Diagnostic is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Suraksha Diagnostic Limited operates a chain of diagnostic centers in India.
Show more
Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity test. In addition, the company provides dental, physiotherapy, immunology & rheumatology, eye, fetal care, ENT, and speciality clinics, as well as home doctor visit services. The company was founded in 1992 and is based in Kolkata, India.
Stock analysis
Suraksha Diagnostic Limited (SURAKSHA) currently trades at ₹350.15, while our model-based Fair Value estimate is ₹135.97, 61.2% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹148.21 per share, and 0 of the 24 models we run sit above the ₹350.15 price.
Bear case: the Asset-Based group reads lowest at ₹31.50, and 24 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹74.61 (bear) to ₹169.96 (bull), the price of ₹350.15 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Suraksha Diagnostic Limited reported revenue of ₹3.1B in FY2026 versus ₹2.2B in FY2022, a compound +8.6%/yr. Reported net income was ₹322M in FY2026, compounding +11.5%/yr from FY2022.
Key figures
Market cap ₹18.2B (≈ $189M) · P/E ratio 50.8 · P/S ratio 5.27 · EPS (TTM) ₹6.89 · Net margin 10.4% · Return on equity 13.8% · Return on assets (EBIT) 11.8% · Operating margin 21.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 2% below its 52-week high and 54% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −61%, SURAKSHA screens richer than that median.
Fair Value models
Bear ₹74.61Fair Value ₹135.97Bull ₹169.96
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹3.49 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+23.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.3%
Start year 2021 (pandemic)
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+1.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.2%
Dividend (yield on the price)0.0%
Profit margin 2022 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 18%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+59.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +53.0% a year for the price.
Compare Suraksha Diagnostic Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 131 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score54 · Below median
Fair Value upside−61.2% · Below median
Profitability
Return on equity (TTM)13.8% · Top 25%
Return on assets8.7% · Top 25%
Net margin (TTM)11.0% · Above median
Operating margin (TTM)21.8% · Top 25%
Growth and dividend
Revenue growth20.7% · Top 25%
Dividend yield (TTM)0.0% · Bottom 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (TTM)50.8× · Pricier than median
P/B7.45× · Priciest 25%
P/S (TTM)5.60× · Pricier than median
P/FCF108.5× · Priciest 25%
EV/EBITDA16.8× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 28
PAST (return on equity)55· sector 9
HEALTH (low debt)100· sector 94
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Suraksha Diagnostic Limited (SURAKSHA) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of ₹135.97 versus a price of ₹350.15, about −61% upside (overvalued).
What is the fair value of SURAKSHA?
Our model-based fair value for Suraksha Diagnostic Limited is ₹135.97 (as of Oct 2, 2026), built from audited fundamentals. The current price: ₹350.15.
What is the quality score of SURAKSHA?
Suraksha Diagnostic Limited has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Suraksha Diagnostic Limited (SURAKSHA)?
Our model-based price target is the fair value of ₹135.97 (as of Oct 2, 2026) from 24 valuation models. Cautious scenario ₹74.61, optimistic scenario ₹169.96. It is a calculation from audited fundamentals, not an analyst target.
What is the Suraksha Diagnostic Limited stock forecast for 2026?
Our models put fair value at ₹135.97, about −61% upside versus a price of ₹350.15 (overvalued). Cautious scenario ₹74.61, optimistic scenario ₹169.96. The calculation is refreshed regularly with new filings.
What is the revenue of Suraksha Diagnostic Limited (SURAKSHA)?
Suraksha Diagnostic Limited reported trailing-twelve-month revenue of about ₹3.3B (latest available figure, as of Oct 2, 2026).
What growth is priced into Suraksha Diagnostic Limited (SURAKSHA)?
For today's price to be fair in a discounted-cash-flow model, Suraksha Diagnostic Limited would have to grow free cash flow by +59.3 % per year for five years (discount rate 15.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.3 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of SURAKSHA use?
Our models discount Suraksha Diagnostic Limited at 15.4 %: a base by market capitalisation (micro), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Suraksha Diagnostic Limited that is +59.3 % per year a year over ten years, using the same discount rate (15.4 %) and the same formula as our fair value.
How much growth has Suraksha Diagnostic Limited (SURAKSHA) delivered so far?
Over the past 5 years revenue at Suraksha Diagnostic Limited grew +17.3 % a year. The price currently implies +59.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Suraksha Diagnostic Limited (SURAKSHA) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Suraksha Diagnostic Limited (+59.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Suraksha Diagnostic Limited (SURAKSHA)?
The free-cash-flow yield on the price is 0.92 %: that much free cash flow Suraksha Diagnostic Limited produces per unit of market value. When it exceeds the discount rate of our models (15.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Suraksha Diagnostic Limited (SURAKSHA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Suraksha Diagnostic Limited it is ₹135.97 per share (as of Oct 2, 2026), against a price of ₹350.15. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Suraksha Diagnostic Limited stock overvalued or undervalued in 2026?
As of Oct 2, 2026, SURAKSHA trades above its calculated fair value: price ₹350.15, fair value ₹135.97, a gap of about −61% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SURAKSHA?
No. The price is what the market pays today (₹350.15); the fair value is what the company's own numbers justify (₹135.97). For Suraksha Diagnostic Limited the two are ₹214.18 per share apart. That gap is exactly why we show both numbers side by side.
How much is Suraksha Diagnostic Limited worth?
The market values Suraksha Diagnostic Limited at about ₹18.2B (market capitalisation, as of Oct 2, 2026). Per share that is ₹350.15; our models calculate a fair value of ₹135.97 per share.
What do the bullish and bearish scenarios say about SURAKSHA?
Our models span a range for Suraksha Diagnostic Limited: cautious scenario ₹74.61, base ₹135.97, optimistic ₹169.96 per share (as of Oct 2, 2026, price ₹350.15). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SURAKSHA?
Suraksha Diagnostic Limited trades at a price-to-earnings ratio of 50.8 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹135.97 is built from several models across several years. Other multiples: P/B 7.5, P/S 5.6, EV/EBITDA 16.8.
How solid is the balance sheet of Suraksha Diagnostic Limited (SURAKSHA)?
Balance-sheet figures for Suraksha Diagnostic Limited (as of Oct 2, 2026): return on equity 13.8%, debt of 0.00 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is SURAKSHA from its 52-week high?
Suraksha Diagnostic Limited trades at ₹350.15, about 2% below its 52-week high of ₹356.00 and 54% above the low of ₹227.60 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹135.97 is for.
Which stocks are comparable to Suraksha Diagnostic Limited?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Suraksha Diagnostic Limited stock attractive at the current price?
The data as of Oct 2, 2026: price ₹350.15, calculated fair value ₹135.97 (−61%), Quality Score 54/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SURAKSHA calculated?
We run Suraksha Diagnostic Limited through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹135.97, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Suraksha Diagnostic Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Suraksha Diagnostic Limited (SURAKSHA)?
The closing price on Oct 1, 2026 was ₹350.15. Our model-based fair value is ₹135.97, about −61% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Suraksha Diagnostic Limited right now?
The price sits above even our optimistic bull case (₹169.96). The favourable scenario is already priced in. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹74.61 to ₹169.96) leaves room in how you read the outcome.
Key figures of Suraksha Diagnostic Limited
How large is the market capitalisation of Suraksha Diagnostic Limited (SURAKSHA)?
The market capitalisation of Suraksha Diagnostic Limited is ₹18.2B (≈ $189M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Suraksha Diagnostic Limited (SURAKSHA)?
The price-to-sales ratio of Suraksha Diagnostic Limited is 5.27 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Suraksha Diagnostic Limited (SURAKSHA)?
Earnings per share at Suraksha Diagnostic Limited are ₹6.89 (price ÷ EPS = P/E 50.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Suraksha Diagnostic Limited (SURAKSHA)?
The net margin of Suraksha Diagnostic Limited is 10.4% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Suraksha Diagnostic Limited (SURAKSHA)?
The return on equity (ROE) of Suraksha Diagnostic Limited is 13.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Suraksha Diagnostic Limited (SURAKSHA)?
On an EBIT basis the return on assets of Suraksha Diagnostic Limited is 11.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Suraksha Diagnostic Limited (SURAKSHA)?
The operating margin of Suraksha Diagnostic Limited is 21.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Suraksha Diagnostic Limited (SURAKSHA)?
Revenue at Suraksha Diagnostic Limited is growing +20.7% versus a year earlier (3y avg +17.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Suraksha Diagnostic Limited (SURAKSHA)?
Earnings per share at Suraksha Diagnostic Limited are growing +38.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Suraksha Diagnostic Limited (SURAKSHA) carry?
The net debt of Suraksha Diagnostic Limited is ₹1.0B (fiscal year 2026, ≈ 6.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Suraksha Diagnostic Limited in the live analysis
One click puts Suraksha Diagnostic Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
